Butcher Eugene C
Department of Pathology, Stanford University, Stanford, California 94305-5324, USA.
Nat Rev Drug Discov. 2005 Jun;4(6):461-7. doi: 10.1038/nrd1754.
The focus of innovation in current drug discovery is on new targets, yet compound efficacy and safety in biological models of disease - not target selection - are the criteria that determine which drug candidates enter the clinic. We consider a biology-driven approach to drug discovery that involves screening compounds by automated response profiling in disease models based on complex human-cell systems. Drug discovery through cell systems biology could significantly reduce the time and cost of new drug development.
当前药物研发的创新重点在于新靶点,然而,决定哪些候选药物进入临床的标准是疾病生物学模型中的化合物疗效和安全性,而非靶点选择。我们考虑一种以生物学为驱动的药物研发方法,该方法涉及基于复杂人类细胞系统,通过疾病模型中的自动反应谱筛选化合物。通过细胞系统生物学进行药物研发可显著减少新药开发的时间和成本。